Difference between revisions of "Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3) (Q10740)"

Latest revision as of 19:25, 24 June 2020

Publication: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response"published as Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32; DOI: 10.1007/s11886-020-01292-3

Language	Label	Description	Also known as
English	Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3)	Publication: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response"published as Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32; DOI: 10.1007/s11886-020-01292-3

Statements

instance of

Segment

0 references

occurs in

Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response (DOI: 10.1007/s11886-020-01292-3)

0 references

part of

Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response (DOI: 10.1007/s11886-020-01292-3)

0 references

IMRaD(C) Section

Methods

0 references

Section or subsection level in publication

Main section in publication

0 references

Has Sectioning

Section 1: Introduction (from DOI: 10.1007/s11886-020-01292-3)

0 references

Section 2: Biology of SARS-CoV-2 (from DOI: 10.1007/s11886-020-01292-3)

0 references

Section 3: The Role of Host Immune Response (from DOI: 10.1007/s11886-020-01292-3)

0 references

Section 4: Viral Toxicity and Myocardial Injury in COVID-2 (from DOI: 10.1007/s11886-020-01292-3)

0 references

Section 5: Immune Responses to SARS-CoV-2 Infection and the Heart (from DOI: 10.1007/s11886-020-01292-3)

0 references

Section 6: Host-Specific Variations in COVID-19 Immune Response (from DOI: 10.1007/s11886-020-01292-3)

0 references

Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3)

0 references

Section 8: Conclusion (from DOI: 10.1007/s11886-020-01292-3)

0 references

Conflict of Interest (from DOI: 10.1007/s11886-020-01292-3)

0 references

References (from DOI: 10.1007/s11886-020-01292-3)

0 references

named entity

COVID-19 (disease - MeSH supplementary concept)

0 references

surface glycoprotein (gene)

0 references

seryl-tRNA synthetase 2, mitochondrial (gene)

0 references

transmembrane serine protease 2 (gene)

0 references

angiotensin I converting enzyme 2 (gene)

0 references

2019 novel coronavirus (species)

0 references

Serine (chemical - MeSH descriptor)

0 references

Cardiovascular Diseases (disease - MeSH descriptor)

0 references

Infections (disease - MeSH descriptor)

0 references

Human (species)

0 references

remdesivir (chemical - MeSH supplementary concept)

0 references

Hydroxychloroquine (chemical - MeSH descriptor)

0 references

Hyperkinesis (disease - MeSH descriptor)

0 references

Sepsis (disease - MeSH descriptor)

0 references

Zika virus (species)

0 references

Azithromycin (chemical - MeSH descriptor)

0 references

lopinavir-ritonavir drug combination (chemical - MeSH supplementary concept)

0 references

Chloroquine (chemical - MeSH descriptor)

0 references

Malaria (disease - MeSH descriptor)

0 references

Cardiac Death (disease - MeSH descriptor)

0 references

Cardiotoxicity (disease - MeSH descriptor)

0 references

interleukin 6 (gene)

0 references

basigin (Ok blood group) (gene)

0 references

programmed cell death 1 (gene)

0 references

tumor necrosis factor (gene)

0 references

tocilizumab (chemical - MeSH supplementary concept)

0 references

sarilumab (chemical - MeSH supplementary concept)

0 references

eculizumab (chemical - MeSH supplementary concept)

0 references

Adalimumab (chemical - MeSH descriptor)

0 references

Acute Respiratory Distress Syndrome (disease - MeSH descriptor)

0 references

Myocarditis (disease - MeSH descriptor)

0 references

Collection or Dataset of Origin

Pubtator Central BioC-JSON formatted article files

0 references

Sitelinks

⧼wikibase-sitelinks-sliswiki⧽(1 entry)

sliswiki Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3)

@@ Property / occurs in / Property / occurs in @@
-Q10356 (Deleted Item)
+Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response (DOI: 10.1007/s11886-020-01292-3)
@@ Property / part of / Property / part of @@
-Q10356 (Deleted Item)
+Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response (DOI: 10.1007/s11886-020-01292-3)
@@ Property / named entity @@
+transmembrane serine protease 2 (gene)
@@ Property / named entity: transmembrane serine protease 2 (gene) / rank @@
+Normal rank
@@ Property / named entity @@
+angiotensin I converting enzyme 2 (gene)
@@ Property / named entity: angiotensin I converting enzyme 2 (gene) / rank @@
+Normal rank
@@ Property / named entity @@
+novel coronavirus (species)
@@ Property / named entity: 2019 novel coronavirus (species) / rank @@
+Normal rank
@@ Property / named entity @@
+Serine (chemical - MeSH descriptor)
@@ Property / named entity: Serine (chemical - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Cardiovascular Diseases (disease - MeSH descriptor)
+Normal rank
@@ Property / named entity @@
+Infections (disease - MeSH descriptor)
@@ Property / named entity: Infections (disease - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Human (species)
@@ Property / named entity: Human (species) / rank @@
+Normal rank
@@ Property / named entity @@
+remdesivir (chemical - MeSH supplementary concept)
+Normal rank
@@ Property / named entity @@
+Hydroxychloroquine (chemical - MeSH descriptor)
@@ Property / named entity: Hydroxychloroquine (chemical - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Hyperkinesis (disease - MeSH descriptor)
@@ Property / named entity: Hyperkinesis (disease - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Sepsis (disease - MeSH descriptor)
@@ Property / named entity: Sepsis (disease - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Drug-Related Side Effects and Adverse Reactions (disease - MeSH descriptor)
+Normal rank
@@ Property / named entity @@
+Zika virus (species)
@@ Property / named entity: Zika virus (species) / rank @@
+Normal rank
@@ Property / named entity @@
+Azithromycin (chemical - MeSH descriptor)
@@ Property / named entity: Azithromycin (chemical - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+lopinavir-ritonavir drug combination (chemical - MeSH supplementary concept)
+Normal rank
@@ Property / named entity @@
+Chloroquine (chemical - MeSH descriptor)
@@ Property / named entity: Chloroquine (chemical - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Malaria (disease - MeSH descriptor)
@@ Property / named entity: Malaria (disease - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Cardiac Death (disease - MeSH descriptor)
@@ Property / named entity: Cardiac Death (disease - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Cardiotoxicity (disease - MeSH descriptor)
@@ Property / named entity: Cardiotoxicity (disease - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+interleukin 6 (gene)
@@ Property / named entity: interleukin 6 (gene) / rank @@
+Normal rank
@@ Property / named entity @@
+basigin (Ok blood group) (gene)
@@ Property / named entity: basigin (Ok blood group) (gene) / rank @@
+Normal rank
@@ Property / named entity @@
+programmed cell death 1 (gene)
@@ Property / named entity: programmed cell death 1 (gene) / rank @@
+Normal rank
@@ Property / named entity @@
+tumor necrosis factor (gene)
@@ Property / named entity: tumor necrosis factor (gene) / rank @@
+Normal rank
@@ Property / named entity @@
+tocilizumab (chemical - MeSH supplementary concept)
+Normal rank
@@ Property / named entity @@
+sarilumab (chemical - MeSH supplementary concept)
+Normal rank
@@ Property / named entity @@
+eculizumab (chemical - MeSH supplementary concept)
+Normal rank
@@ Property / named entity @@
+Adalimumab (chemical - MeSH descriptor)
@@ Property / named entity: Adalimumab (chemical - MeSH descriptor) / rank @@
+Normal rank
@@ Property / named entity @@
+Acute Respiratory Distress Syndrome (disease - MeSH descriptor)
+Normal rank
@@ Property / named entity @@
+Myocarditis (disease - MeSH descriptor)
@@ Property / named entity: Myocarditis (disease - MeSH descriptor) / rank @@
+Normal rank
@@ Property / Collection or Dataset of Origin @@
+Pubtator Central BioC-JSON formatted article files
+Normal rank

Difference between revisions of "Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3) (Q10740)"

Latest revision as of 19:25, 24 June 2020

Statements

Sitelinks

⧼wikibase-sitelinks-sliswiki⧽(1 entry)

Navigation menu

Personal tools

Namespaces

Variants

Views

More

Search

Navigation

Tools

In other languages